SLE与γ干扰素的基因型及血清水平的相关性  

The Serum Level and Genotype of Interferon-gamma in Patients with Systematic Lupus Erythematosus.

作　　者：蓝艳[1] 唐秀生[1] 武洁[1] 陈集敏[1] 覃俊[1] 

机构地区：[1]右江民族医学院附属医院皮肤科,广西百色533000

出　　处：《中国皮肤性病学杂志》2009年第2期81-83,共3页The Chinese Journal of Dermatovenereology

基　　金：广西教育厅基金资助项目(200610MS020)

摘　　要：目的观察γ干扰素(IFN-γ)基因多态性各等位基因及基因型在系统性红斑狼疮(SLE)中的分布频率,初步分析其基因型及血清水平与SLE的相关性。方法采用序列特异性引物-聚合酶链反应(PCR-SSP)技术检测120例SLE患者和150名正常对照者IFN-γ的基因+874 A/T多态性,同时采用酶联免疫吸附试验(ELISA)检测血清IFN-γ水平。结果SLE组血清IFN-γ水平与对照组比较明显升高,且差异有显著性意义(P<0.05),IFN-γ基因+874 A/T多态性在两组人群中的分布差异有显著性意义(P<0.05),T等位基因携带者患SLE的风险是A等位基因的1.737倍(OR= 1.737,95%CI:1.193～2.529),携带T等位基因的SLE患者血清IFN-γ水平与不携带者比较明显升高,且差异有显著性意义(P<0.05)。结论IFN-γ基因+874 A/T多态性与SLE的发病具有相关性,T等位基因可能是SLE发病的遗传易感基因;携带T等位基因的个体可能通过促进IFN-γ的高度表达增加了SLE的发病风险。Objective To study the relationship the allele frequencies and genotype distribution of Interferon-gamma （IFN-γ） gene polymorphism in patients with systematic lupus erythematosus （SLE） ,And to analyze association the serum levels and genotype of IFN-γ with SLE. Methods IFN-γ gene ＋ 874 A/T polymorphism was analyzed by the sequence specific primers - polymerase chain reaction（PCR -SSP） methods in 120 patients with SLE and 150 healthy controls, and the serum level of IFN-γ was determined by enzyme-linked immunosorbent assay （ELISA）. Results The SLE group showed significantly higher serum levels of IFN-γ, than that in control group （P 〈 0.05）, The distributions of IFN-γ gene ＋ 874 A/T polymorphism was significantly different between SLE group and control group. The relative risk suffered from SLE of T allele was 1. 737 times higher than that of A allele （ OR = 1. 737,95% CI ： 1. 193 - 2.529）, the serum level of IFN-γ T allele carriers was significantly higher than that of no carriers （P 〈 0.05）. Conclusion IFN-γ gene ＋ 874 A/T polymorphism was associated with SLE, and T allele may be a risk factor for SLE. In which the IFN-γ T allele carriers may be increase risk by enhancing the IFN-γ expression in the pathogenesis of SLE.

关 键 词：系统性红斑狼疮 干扰素1 基因型 

分 类 号：R593.241[医药卫生—内科学] Q503[医药卫生—临床医学]